Identification of a Glycosylation‐Related Gene Prognostic Signature for Non–Small Cell Lung Cancer
- 1Department of Thoracic Surgery Hebei General Hospital Shijiazhuang Hebei China
Abstract
Purpose: A prognostic signature for non–small cell lung cancer (NSCLC) was developed through identification and integration of glycosylation‐related genes (GRGs).
Methods: TCGA RNA‐seq data for LUAD and LUSC were analyzed. GRGs were intersected with differentially expressed genes; prognostic GRGs were selected via Cox and LASSO regression to construct a risk model. The immune microenvironment and immunotherapy responses were compared between risk groups. An miRNA–mRNA–transcription factor (TF) network was built and potential drugs were predicted. ADAMTS15 expression was verified by RT‐qPCR in NSCLC tissues and cell lines; functional assays (CCK‐8, wound healing, Transwell) were performed after ADAMTS15 knockdown in A549 (LUAD) and NCI‐H520 (LUSC) cells.
Results: A total of 134 differentially expressed GRGs were identified. Ten genes (ADAMTS15, PCSK9, MUC2, B3GNT3, etc.) were selected for the prognostic model, which functioned as an independent prognostic factor. High‐risk patients showed poorer immunotherapy response. The regulatory network included 30 TFs and 142 miRNAs, with 107 drug–target pairs predicted. ADAMTS15 was elevated in NSCLC; its knockdown inhibited proliferation, migration, and invasion in both LUAD and LUSC cell models.
Conclusion: A 10‐gene prognostic signature derived from GRGs was identified. Functional validation affirmed ADAMTS15's tumor‐promoting role, offering insights for NSCLC prognosis and targeted therapy.
Related
- Identification of a DNA Damage Response-Related Prognostic Signature and Functional Validation of SMC3 in Glioma
- Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines
- Identification of prognostic biomarkers for nasopharyngeal carcinoma through microRNA‑mRNA network analysis combined with screening of immune‑related genes
- Identification of Glycosylation-Associated Proteins in Colostrum: A Review of Mass Spectrometry-Based Strategies.
- Two-Trace Two-Dimensional Correlation Analysis for the Confirmation of Therapeutic Protein Identification and Evaluation of Extent of Glycosylation: A Rapid Method for Testing Critical Quality Attributes
BibTeX
@article{zhao2026identification,
title = {{Identification of a Glycosylation‐Related Gene Prognostic Signature for Non–Small Cell Lung Cancer}},
author = {Qingtao Zhao and Xiaopeng Zhang and Guochen Duan},
journal = {The Journal of Gene Medicine},
year = {2026},
month = oct,
doi = {10.1002/jgm.70121},
url = {https://doi.org/10.1002/jgm.70121},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Identification of a Glycosylation‐Related Gene Prognostic Signature for Non–Small Cell Lung Cancer
AU - Qingtao Zhao
AU - Xiaopeng Zhang
AU - Guochen Duan
PY - 2026
DA - 2026/10/27
JO - The Journal of Gene Medicine
DO - 10.1002/jgm.70121
UR - https://doi.org/10.1002/jgm.70121
AB - Purpose: A prognostic signature for non–small cell lung cancer (NSCLC) was developed through identification and integration of glycosylation‐related genes (GRGs). Methods: TCGA RNA‐seq data for LUAD and LUSC were analyzed. GRGs were intersected with differentially expressed genes; prognostic GRGs were selected via Cox and LASSO regression to construct a risk model. The immune microenvironment and immunotherapy responses were compared between risk groups. An miRNA–mRNA–transcription factor (TF) network was built and potential drugs were predicted. ADAMTS15 expression was verified by RT‐qPCR in NSCLC tissues and cell lines; functional assays (CCK‐8, wound healing, Transwell) were performed after ADAMTS15 knockdown in A549 (LUAD) and NCI‐H520 (LUSC) cells. Results: A total of 134 differentially expressed GRGs were identified. Ten genes (ADAMTS15, PCSK9, MUC2, B3GNT3, etc.) were selected for the prognostic model, which functioned as an independent prognostic factor. High‐risk patients showed poorer immunotherapy response. The regulatory network included 30 TFs and 142 miRNAs, with 107 drug–target pairs predicted. ADAMTS15 was elevated in NSCLC; its knockdown inhibited proliferation, migration, and invasion in both LUAD and LUSC cell models. Conclusion: A 10‐gene prognostic signature derived from GRGs was identified. Functional validation affirmed ADAMTS15's tumor‐promoting role, offering insights for NSCLC prognosis and targeted therapy.
SN - 1099-498X
SN - 1521-2254
ER -